- Reunion Neuroscience (REUN) has filed a lawsuit against Mindset Pharma in the United States District Court
- The company alleges that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented it to the Patent Office as Mindset’s invention
- Reunion has also asserted claims for co-ownership of the ‘353 Patent and breach of contract
- Reunion Neuroscience early-stage pharmaceutical company developing therapeutic solutions for mental health conditions
- Reunion Neuroscience Inc. (TSX:REUN) opened trading at C$1.18
Reunion Neuroscience (REUN) has filed a lawsuit against Mindset Pharma in the United States District Court for the District of New Jersey.
The company alleges that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset’s invention while applying for U.S. Patent No. 11,591,353 (‘353 Patent). Reunion seeks to add the original and sole inventor of Reunion’s RE104, Reunion’s Chief Scientific Officer, Dr. Nathan Bryson, as an inventor of the ‘353 Patent.
Reunion has also asserted claims for co-ownership of the ‘353 Patent, inequitable conduct in the prosecution of the ‘353 Patent, and breach of contract.
About Reunion Neuroscience Inc.
Reunion Neuroscience early-stage pharmaceutical company developing therapeutic solutions for mental health conditions. The company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound, is being developed as a potential treatment for postpartum depression that could provide rapid symptom relief. Reunion is also developing the RE200 series, which includes preclinical compounds to address additional therapeutic applications.
Reunion Neuroscience Inc. (TSX:REUN) opened trading at C$1.18.
